Ubiquitin-like protein conjugation and the ubiquitin–proteasome system as drug targets
Top Cited Papers
- 10 December 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Drug Discovery
- Vol. 10 (1), 29-46
- https://doi.org/10.1038/nrd3321
Abstract
Ubiquitin is a highly conserved 76 amino-acid protein that covalently attaches to protein substrates targeted for degradation by the 26S proteasome. The coordinated effort of a series of enzymes, including an activating enzyme (E1), a conjugating enzyme (E2) and a ligase (E3), uses ATP to ultimately form an isopeptide bond between ubiquitin and a substrate.Another class of enzymes called deubiquitylating enzymes (DUBs) deconstruct these linkages and also have an essential role in ubiquitin function. In addition, ubiquitin-like proteins (UBLs), including NEDD8, SUMO and ISG15, share a characteristic three-dimensional fold with ubiquitin but have their own dedicated enzyme cascades and distinct (although sometimes overlapping) biological functions.The ubiquitin–proteasome system (UPS) and UBL conjugation pathways have important roles in various human diseases, including numerous types of cancer, cardiovascular disease, viral diseases and neurodegenerative disorders. The proteasome inhibitor bortezomib (Velcade; Millennium Pharmaceuticals) is the first clinically validated drug to target the UPS and is approved for the treatment of multiple myeloma. This suggests that other diseases may conceivably be targeted by modulating components of the UPS and UBL conjugation pathways using small-molecule inhibitors.A significant hurdle to identifying drug-like inhibitors of enzyme targets within the UPS and UBL conjugation pathways is the limited understanding of the molecular mechanisms and biological consequences of UBL conjugation.Here, we provide an overview of the enzyme classes in the UPS and UBL pathways that are potential therapeutic targets, and highlight considerations that are important for drug discovery. We also discuss the progress in the development of small-molecule inhibitors, and review developments in understanding of the role of the components of the UPS and the UBL pathways in disease and their potential for therapeutic intervention.Keywords
This publication has 137 references indexed in Scilit:
- “Depupylation” of Prokaryotic Ubiquitin-like Protein from Mycobacterial Proteasome SubstratesMolecular Cell, 2010
- Defining the Human Deubiquitinating Enzyme Interaction LandscapeCell, 2009
- The ubiquitin proteasome system in neuropathologyActa Neuropathologica, 2009
- Allosteric Activation of E2-RING Finger-Mediated Ubiquitylation by a Structurally Defined Specific E2-Binding Region of gp78Molecular Cell, 2009
- Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced InflammationCell, 2009
- Oxygen‐independent degradation of HIF‐α via bioengineered VHL tumour suppressor complexEMBO Molecular Medicine, 2009
- Structural Insights into NEDD8 Activation of Cullin-RING Ligases: Conformational Control of ConjugationCell, 2008
- Roles of ubiquitination at the synapseBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2008
- IAPs: What's in a Name?Molecular Cell, 2008
- Salinosporamide A: A Highly Cytotoxic Proteasome Inhibitor from a Novel Microbial Source, a Marine Bacterium of the New Genus SalinosporaAngewandte Chemie, 2003